IP Library › Patent Application 18949157
Patent Application
App. No. 18/949,157

OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES RELATING THERETO

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/949,157
Abstract

The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.

Claims (28)

1 - 70 . (canceled)

71 . An ophthalmic pharmaceutical composition comprising one therapeutically active component, wherein the therapeutically active component is pilocarpine or a pharmaceutically acceptable salt thereof at a concentration of 0.2% to 0.4% (w/w or w/v);

hydroxypropyl methylcellulose;

sodium hyaluronate;

one or more pH agents;

one or more solvents;

one or more tonicity agents;

ethylenediaminetetraacetic acid or a salt thereof; and

a pharmaceutically acceptable carrier.

72 . The ophthalmic pharmaceutical composition of claim 71 , wherein the pilocarpine salt is pilocarpine hydrochloride.

73 . The ophthalmic pharmaceutical composition of claim 72 , wherein the pilocarpine hydrochloride is present at a concentration of 0.4% (w/w or w/v).

74 . The ophthalmic pharmaceutical composition of claim 71 , wherein the sodium hyaluronate is present at a concentration of 0.01% to 0.9% (w/w or w/v).

75 . The ophthalmic pharmaceutical composition of claim 71 , wherein the hydroxypropyl methylcellulose is present at a concentration of 0.1% to 2.0% (w/w or w/v).

76 . The ophthalmic pharmaceutical composition of claim 71 , wherein the hydroxypropyl methylcellulose is present at a concentration of 0.8% (w/w or w/v).

77 . The ophthalmic pharmaceutical composition of claim 71 , wherein the sodium hyaluronate is present at a concentration of 0.1% (w/w or w/v).

78 . The ophthalmic pharmaceutical composition of claim 71 , wherein the tonicity agent comprises sodium chloride.

79 . The ophthalmic pharmaceutical composition of claim 71 , wherein the ophthalmic pharmaceutical composition comprises pilocarpine or a pharmaceutically acceptable salt thereof at a concentration of 0.4% (w/w or w/v), hydroxypropyl methylcellulose at a concentration of 0.8% (w/w or w/v), sodium hyaluronate at a concentration of 0.1% (w/w or w/v), and sodium chloride.

80 . An ophthalmic pharmaceutical composition comprising one therapeutically active component, wherein the therapeutically active component is pilocarpine hydrochloride at a concentration of 0.4% (w/w or w/v); hydroxypropyl methylcellulose at a concentration of 0.8% (w/w or w/v); sodium hyaluronate at a concentration of 0.1% (w/w or w/v); and at least one pharmaceutically acceptable carrier.

81 . The ophthalmic pharmaceutical composition of claim 80 , further comprising a tonicity agent.

82 . The ophthalmic pharmaceutical composition of claim 81 , wherein the tonicity agent comprises sodium chloride.

83 . The ophthalmic pharmaceutical composition of claim 80 , further comprising a stabilizer agent.

84 . The ophthalmic pharmaceutical composition of claim 80 , further comprising ethylenediaminetetraacetic acid or a salt thereof.

85 . The ophthalmic pharmaceutical composition of claim 80 , further comprising one or more pH agents.

86 . The ophthalmic pharmaceutical composition of claim 80 , further comprising sodium chloride, ethylenediaminetetraacetic acid or a salt thereof, and one or more pH agents.

87 . An ophthalmic pharmaceutical composition consisting of pilocarpine hydrochloride at a concentration of 0.4% (w/w or w/v); hydroxypropyl methylcellulose at a concentration of 0.8% (w/w or w/v); sodium hyaluronate at a concentration of 0.1% (w/w or w/v); and at least one pharmaceutically acceptable carrier and/or excipient.

88 . The ophthalmic pharmaceutical composition of claim 87 , wherein the at least one pharmaceutically acceptable carrier and/or excipient comprises sodium chloride, ethylenediaminetetraacetic acid or a salt thereof, and one or more pH agents.

89 . A method of treating presbyopia, comprising administering the ophthalmic pharmaceutical composition of claim 71 to a patient in need thereof.

90 . A method of treating presbyopia, comprising administering the ophthalmic pharmaceutical composition of claim 79 to a patient in need thereof.